Impact of tumor hypoxia and anemia on radiation therapy outcomes

Oncologist

Volumn 7, Issue 6, 2002, Pages 492-508

  Harrison, Louis B ^a   Chadha, Manjeet ^a   Hill, Richard J ^b   Hu, Kenneth ^a   Shasha, Daniel ^a  

^a BETH ISRAEL MEDICAL CENTER   (United States)

^b Ortho Biotech Products LP   (United States)

Author keywords

Anemia; Anoxia; Epoetin alfa; Neoplasms; Radiation therapy; Treatment outcome

Indexed keywords

CARBOGEN; FLUOSOL;

ANEMIA; CANCER CONTROL; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; HEAD AND NECK CANCER; HEMOGLOBIN DETERMINATION; HUMAN; HYPERBARIC OXYGEN; HYPOXIA; OXYGEN TENSION; PRIORITY JOURNAL; PROGNOSIS; RADIOSENSITIVITY; REVIEW; TREATMENT OUTCOME; UTERINE CERVIX CANCER;

ANEMIA; ANOXIA; DOSE-RESPONSE RELATIONSHIP, RADIATION; HEAD AND NECK NEOPLASMS; HUMANS; NEOPLASM RECURRENCE, LOCAL; OXYGEN; PROGNOSIS; RADIATION-SENSITIZING AGENTS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0036918282     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.7-6-492     Document Type: Review

References (153)

1. Feldmann HJ, Molls M, Vaupel P. Blood flow and oxygenation status of human tumors: Clinical investigations. Strahlenther Onkol 1999;175:1-9.
2. Mundt AJ, Connell PP, Campbell T et al. Race and clinical outcome in patients with carcinoma of the uterine cervix treated with radiation therapy. Gynecol Oncol 1998;71:151-158.
3. Takeshi K, Katsuyuki K, Yoshiaki T et al. Definitive radiotherapy combined with high-dose-rate brachytherapy for stage III carcinoma of the uterine cervix: Retrospective analysis of prognostic factors concerning patient characteristics and treatment parameters. Int J Radiat Oncol Biol Phys 1998;41:319-327.
4. Okunieff P, de Bie J, Dunphy EP et al. Oxygen distributions partly explain the radiation response of human squamous cell carcinomas. Br J Cancer 1996;27(suppl):S185-S190.
5. Teicher BA. Physiologic mechanisms of therapeutic resistance: Blood flow and hypoxia. Hematol Oncol Clin North Am 1995;9:475-506.
6. Harrison LB, Shasha D, Shiaova L et al. Prevalence of anemia in cancer patients undergoing radiotherapy. Proc Am Soc Clin Oncol 2000;19:471a.
7. Evans SM, Jenkins WT, Shapiro M et al. Evaluation of the concept of "hypoxic fraction" as a descriptor of tumor oxygenation status. Adv Exp Med Biol 1997;411:215-225.
8. Jund R, Feldmann H-J, Wollenberg B et al. Changes in head and neck tumor hypoxic fraction during split-course radiochemotherapy. Ann Otol Rhinol Laryngol 1999;108:73-78.
9. Molls M, Stadler P, Becker A et al. Relevance of oxygen in radiation oncology: Mechanisms of action, correlation to low hemoglobin levels. Strahlenther Onkol 1998;174(suppl 4):13-16.
10. Rockwell S. Oxygen delivery: Implications for the biology and therapy of solid tumors. Oncol Res 1997;9:383-390.
11. Stüben G, Stuschke M, Knühmann K et al. The effect of combined nicotinamide and carbogen treatments in human tumour xenografts: Oxygenation and tumour control studies. Radiother Oncol 1998;48:143-148.
12. Warde P, O'Sullivan B, Bristow RG et al. T1/T2 glottic cancer managed by external beam radiotherapy: The influence of pretreatment hemoglobin on local control. Int J Radiat Oncol Biol Phys 1998;41:347-353.
13. Hellman S. Principles of cancer management: Radiation therapy. In: DeVita Jr VT, Hellman S, Rosenberg SA, eds. Cancer: Principles & Practice of Oncology, Fifth Edition. Philadelphia: Lippincott-Raven Publishers, 1997:307-331.
14. Alarcón R, Koumenis C, Geyer RK et al. Hypoxia induces p53 accumulation through MDM2 down-regulation and inhibition of E6-mediated degradation. Cancer Res 1999;59:6046-6051.
15. Graeber TG, Osmanian C, Jacks T et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours [letter]. Nature 1996;379:88-91.
16. 2 study. Cancer 2000;89:2018-2024.
17. Kondo A, Safaei R, Mishima M et al. Hypoxia-induced enrichment and mutagenesis of cells that have lost DNA mismatch repair. Cancer Res 2001;61:7603-7607.
18. Reynolds TY, Rockwell S, Glazer PM. Genetic instability induced by the tumor microenvironment. Cancer Res 1996;56:5754-5757.
19. Yuan J, Glazer PM. Mutagenesis induced by the tumor microenvironment. Mutat Res 1998;400:439-446.
20. Yuan J, Narayanan L, Rockwell S et al. Diminished DNA repair and elevated mutagenesis in mammalian cells exposed to hypoxia and low pH. Cancer Res 2000;60:4372-4376.
21. Dunst J, Hänsgen G, Lautenschläiger C et al. Oxygenation of cervical cancers during radiotherapy and radiotherapy + cisretinoic acid/interferon. Int J Radiat Oncol Biol Phys 1999;43:367-373.
22. Stadler P, Feldmann HJ, Creighton C et al. Changes in tumor oxygenation during combined treatment with split-course radiotherapy and chemotherapy in patients with head and neck cancer. Radiother Oncol 1998;48:157-164.
23. Ballinger JR. Imaging hypoxia in tumors. Semin Nucl Med 2001;31:321-329.
24. Blower P, Dilworth JR, Maurer RI et al. Towards new transition metal-based hypoxic selective agents for therapy and imaging. J Inorg Biochem 2001;85:15-22.
25. Dietz A, Rudat V, Vanselow B et al. Rise of oxygenation in cervical lymph node metastasis during the initial course of radiochemotherapy. Otolaryngol Head Neck Surg 1999;121:789-796.
26. 2) during accelerated radiotherapy of head and neck carcinoma [Letter]. Eur J Cancer 1999;35:161-162.
27. 2 predicts survival in advanced cancer of the uterine cervix. Radiother Oncol 1993;26:45-50.
28. Höckel M, Vorndran B, Schlenger K et al. Tumor oxygenation: A new predictive parameter in locally advanced cancer of the uterine cervix. Gynecol Oncol 1993;51:141-149.
29. Höckel M, Schlenger K, Aral B et al. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 1996;56:4509-4515.
30. Brizel DM, Dodge RK, Clough RW et al. Oxygenation of head and neck cancer: Changes during radiotherapy and impact on treatment outcome. Radiother Oncol 1999;53:113-117.
31. Brizel DM, Sibley GS, Prosnitz LR et al. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 1997;38:285-289.
32. Fyles AW, Milosevic M, Wong R et al. Oxygenation predicts radiation response and survival in patients with cervix cancer. Radiother Oncol 1998;48:149-156.
33. 2-measurements as predictive assay in the treatment of carcinoma of the uterine cervix. Radiother Oncol 1999;53:99-104.
34. Nordsmark M, Overgaard M, Overgaard J. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother Oncol 1996;41:31-39.
35. Rofstad EK, Sundfør K, Lyng H et al. Hypoxia-induced treatment failure in advanced squamous cell carcinoma of the uterine cervix is primarily due to hypoxia-induced radiation resistance rather than hypoxia-induced metastasis. Br J Cancer 2000;83:354-359.
36. 2 histography in patients with advanced head and neck cancer. Radiother Oncol 2000;57:31-37.
37. Stadler P, Becker A, Feldmann HJ et al. Influence of the hypoxic subvolume on the survival of patients with head and neck cancer. Int J Radiat Oncol Biol Phys 1999;44:749-754.
38. Strauss HG, Haensgen G, Becker A et al. Prognostic impact of changes in the tumor tissue pO2 during early radiotherapy in cervical cancers: Improved local control in primarily hypoxic tumors with "reoxygenation" and the impact of hemoglobin. Int J Radiat Oncol Biol Phys 1999;45(suppl 1):364.
39. Adelstein DJ, Saxton JP, Lavertu P et al. A phase III randomized trial comparing concurrent chemotherapy and radiotherapy with radiotherapy alone in resectable stage III and IV squamous cell head and neck cancer: Preliminary results. Head Neck 1997;19:567-575.
40. Aquino-Parsons C, Lim P, Green A et al. Carbogen inhalation in cervical cancer: Assessment of oxygenation change. Gynecol Oncol 1999;74:259-264.
41. Keys HM, Bundy BN, Stehman FB et al. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med 1999;340:1154-1161.
42. Harrison LB, Raben A, Pfister DG et al. A prospective phase II trial of concomitant chemotherapy and radiotherapy with delayed accelerated fractionation in unresectable tumors of the head and neck. Head Neck 1998;20:497-503.
43. Morris M, Eifel PJ, Lu J et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med 1999;340:1137-1143.
44. Rose PG, Bundy BN, Watkins EB et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med 1999;340:1144-1153.
45. Stem S, Guichard M. Efficacy of agents counteracting hypoxia in fractionated radiation regimes. Radiother Oncol 1996;41:143-149.
46. Whitney CW, Sause W, Bundy BN et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group Study. J Clin Oncol 1999;17:1339-1348.
47. Brown JM. The hypoxic cell: A target for selective cancer therapy-Eighteenth Bruce F. Cain Memorial Award Lecture. Cancer Res 1999;59:5863-5870.
48. Overgaard J, Horsman MR. Modification of hypoxia-induced radioresistance in tumors by the use of oxygen and sensitizers. Semin Radiat Oncol 1996;6:10-21.
49. Bussink J, Kaanders JH, Van der Kogel AJ. Clinical outcome and tumour microenvironmental effects of accelerated radiotherapy with carbogen and nicotinamide. Acta Oncol 1999;38:875-882.
50. Fenton BM, Lord EM, Paoni SF. Enhancement of tumor perfusion and oxygenation by carbogen and nicotinamide during single- and multifraction irradiation. Radiat Res 2000;153:75-83.
51. Hoskin PJ, Saunders MI, Dische S. Hypoxic radiosensitizers in radical radiotherapy for patients with bladder carcinoma: Hyperbaric oxygen, misonidazole, and accelerated radiotherapy, carbogen, and nicotinamide. Cancer 1999;86:1322-1328.
52. Martinez J, Cabezon M, Fuentes C et al. Hyperfractionated chemoradiotherapy with carbogen breathing for advanced cancer of the head and neck. Int J Radiat Oncol Biol Phys 1999;45(suppl 1):377.
53. Saunders M, Dische S. Clinical results of hypoxic cell radiosensitisation from hyperbaric oxygen to accelerated radiotherapy, carbogen and nicotinamide. Br J Cancer 1996;27(suppl):S271-S278.
54. Bemier J, Denekamp J, Rojas A et al. ARCON: Accelerated radiotherapy with carbogen and nicotinamide in head and neck squamous cell carcinomas. The experience of the Cooperative Group of Radiotherapy of the European Organization for Research and Treatment of Cancer (EORTC). Radiother Oncol 2000;55;111-119.
55. Miralbell R, Momex F, Greiner R et al. Accelerated radiotherapy, carbogen, and nicotinamide in glioblastoma multiforme: Report of European Organization for Research and Treatment of Cancer trial 22933. J Clin Oncol 1999;17;3143-3149.
56. Grigsby PW, Winter K, Wasserman TH et al. Irradiation with or without misonidazole for patients with stages IIIB and IVA carcinoma of the cervix: Final results of RTOG 80-05. Int J Radiat Oncol Biol Phys 1999;44:513-517.
57. Lee DJ, Pajak TF, Stetz J et al. A phase I/II study of the hypoxic cell sensitizer misonidazole as an adjunct to high fractional dose radiotherapy in patients with unresectable squamous cell carcinoma of the head and neck: A RTOG randomized study (#79-04). Int J Radiat Oncol Biol Phys 1989;16:465-470.
58. Lee DJ, Cosmatos D, Marcial VA et al. Results of an RTOG phase III trial (RTOG 85-27) comparing radiotherapy plus etanidazole with radiotherapy alone for locally advanced head and neck carcinomas. Int J Radiat Oncol Biol Phys 1995;32:567-576.
59. Overgaard J, Bentzen SM, Kolstad P et al. Misonidazole combined with radiotherapy in the treatment of carcinoma of the uterine cervix. Int J Radiat Oncol Biol Phys 1989;16:1069-1072.
60. Overgaard J, Hansen HS, Andersen AP et al. Misonidazole combined with split-course radiotherapy in the treatment of invasive carcinoma of larynx and pharynx: Report from the DAHANCA 2 study. Int J Radiat Oncol Biol Phys 1989;16:1065-1068.
61. Overgaard J. Sensitization of hypoxic tumour cells - Clinical experience. Int J Radiat Biol 1989;56:801-811.
62. Overgaard J, Hansen HS, Overgaard M et al. A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85. Radiother Oncol 1998;46:135-146.
63. Wasserman TH, Lee DJ, Cosmatos D et al. Clinical trials with etanidazole (SR-2508) by the radiation therapy oncology group (RTOG). Radiother Oncol 1991;20(suppl 1):129-135.
64. Huncharek M. Meta-analytic re-evaluation of misonidazole in the treatment of high grade astrocytoma. Anticancer Res 1998;18:1935-1939.
65. Eisbruch A, Robertson JM, Johnston CM et al. Bromodeoxyuridine alternating with radiation for advanced uterine cervix cancer: A phase I and drug incorporation study. J Clin Oncol 1999;17:31-40.
66. Rosenthal DI, Nurenberg P, Becerra CR et al. A phase I singledose trial of gadolinium texaphyrin (Gd-Tex), a tumor selective radiation sensitizer detectable by magnetic resonance imaging. Clin Cancer Res 1999;5:739-745.
67. Haffty BG, Son YH, Papac R et al. Chemotherapy as an adjunct to radiation in the treatment of squamous cell carcinoma of the head and neck: Results of the Yale mitomycin randomized trials. J Clin Oncol 1997;15:268-276.
68. Coia LR, Engstrom PF, Paul AR et al. Long-term results of infusional 5-FU, mitomycin-C, and radiation as primary management of esophageal carcinoma. Int J Radiat Oncol Biol Phys 1991;20:29-36.
69. Cummings BJ, Keane TJ, O'Sullivan B et al. Epidermoid anal cancer: Treatment by radiation alone or by radiation and 5-fluorouracil with and without mitomycin C. Int J Radiat Oncol Biol Phys 1991;21:1115-1125.
70. Dobrowsky W. Mitomycin C, 5-fluorouracil and radiation in advanced, locally recurrent rectal cancer. Br J Radiol 1992;65:143-147.
71. Dobrowsky W, Dobrowsky E, Strassl H et al. Response to preoperative concomitant radiochemotherapy with mitomycin C and 5-fluorouracil in advanced head and neck cancer. Eur J Cancer Clin Oncol 1989;25:845-849.
72. Dobrowsky W, Naudé J, Widder J et al. Continuous hyperfractionated accelerated radiotherapy with/without mitomycin C in head and neck cancer. Int J Radiat Oncol Biol Phys 1998;42:803-806.
73. Dobrowsky WH, Naudé J, Widder J et al. Continuous hyperfractionated accelerated radiotherapy and mitomycin C in head and neck cancer. Int J Radiat Oncol Biol Phys 1999;45(suppl 1):148.
74. Roberts KB, Urdaneta N, Vera R et al. Interim results of a randomized trial of mitomycin C as an adjunct to radical radiotherapy in the treatment of locally advanced squamous-cell carcinoma of the cervix. Int J Cancer 2000;90:206-223.
75. Sartorelli AC, Hodnick WF, Belcourt MF et al. Mitomycin C: A prototype bioreductive agent. Oncol Res 1994;6:501-508.
76. Sivanesaratnam V, Jayalakshmi P. Mitomycin C adjuvant chemotherapy after Wertheim's hysterectomy for stage IB cervical cancer. Cancer 1989;64:798-800.
77. Keyes SR, Rockwell S, Sartorelli AC. Enhancement of mitomycin C cytotoxicity to hypoxic tumor cells by dicoumarol in vivo and in vitro. Cancer Res 1985;45:213-216.
78. Keyes SR, Rockwell S, Sartorelli AC. Modification of the metabolism and cytotoxicity of bioreductive alkylating agents by dicoumarol in aerobic and hypoxic murine tumor cells. Cancer Res 1989;49:3310-3313.
79. Rockwell S, Keyes SR, Sartorelli AC. Modulation of the cytotoxicity of mitomycin C to EMT6 mouse mammary tumor cells by dicoumarol in vitro. Cancer Res 1988;48:5471-5474.
80. Rockwell S, Keyes SR, Sartorelli AC. Modulation of the antineoplastic efficacy of mitomycin C by dicoumarol in vivo. Cancer Chemother Pharmacol 1989;24:349-353.
81. Brown JM, Wang LH. Tirapazamine: Laboratory data relevant to clinical activity. Anticancer Drug Des 1998;13:529-539.
82. Keyes SR, Rockwell S, Sartorelli AC. Porfiromycin as a bioreductive alkylating agent with selective toxicity to hypoxic EMT6 tumor cells in vivo and in vitro. Cancer Res 1985;45:3642-3645.
83. Rockwell S, Keyes SR, Sartorelli AC. Preclinical studies of porfiromycin as an adjunct to radiotherapy. Radiat Res 1988;116:100-113.
84. Fischer JJ. Phase III Randomized Study of Mitomycin vs Porfiromycin as an Adjunct to Radiotherapy for Epidermoid Carcinomas of the Head and Neck. Protocol YALE-HIC-6611, NCI-V92-0190. Available at: http://cancemet.nci.nih.gov. Accessed January 10, 2001.
85. Lee DJ, Trotti A, Spencer S et al. Concurrent tirapazamine and radiotherapy for advanced head and neck carcinomas: A phase II study. Int J Radiat Oncol Biol Phys 1998;42:811-815.
86. Craighead PS, Pearcey R, Smart G. A phase I/II evaluation of tirapazamine administered intravenously concurrent with cisplatin and radiotherapy in women with locally advanced cervical cancer. Int J Radiat Oncol Biol Phys 2000;48;791-795.
87. Elsaid AA, Menke D, Dorie MJ et al. Anti-melanoma activity of tirapazamine in combination with dacarbazine (DTIC). Proc Am Soc Clin Oncol 1997;16:505a.
88. Gatzemeier U, Rodriguez G, Treat J et al. Tirapazamine-cisplatin: The synergy. Br J Cancer 1998;77(suppl 4):15-17.
89. Kovacs MS, Hocking DJ, Evans JW et al. Cisplatin antitumour potentiation by tirapazamine results from a hypoxia-dependent cellular sensitization to cisplatin. Br J Cancer 1999;80:1245-1251.
90. Siemann DW, Hinchman CA. Potentiation of cisplatin activity by the bioreductive agent tirapazamine. Radiother Oncol 1998;47:215-220.
91. Treat J, Johnson E, Langer C et al. Tirapazamine with cisplatin in patients with advanced non-small-cell lung cancer: A phase II study. J Clin Oncol 1998;16:3524-3527.
92. Weitman S, Mangold G, Marry J et al. Evidence of enhanced in vivo activity using tirapazamine with paclitaxel and paraplatin regimens against the MV-522 human lung cancer xenograft. Cancer Chemother Pharmacol 1999;43:402-408.
93. Kim C, Pinto HA, Tate D et al. Tirapazamine, cisplatin & fluorouracil as induction chemotherapy & simultaneous chemoradiotherapy for organ preservation in advanced head and neck cancer. Proc Am Soc Clin Oncol 1998;17:395a.
94. Peters LJ, Rischin D, Hicks RJ et al. Extraordinary tumor control in phase I trial of concurrent tirapazamine, cisplatin and radiotherapy for far advanced head and neck cancer. Int J Radiat Oncol Biol Phys 1999;45(suppl 1):148-149.
95. von Pawel J, von Roemeling R, Gatzemeier U et al. Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: A report of the international CATAPULT I study group. J Clin Oncol 2000;18;1351-1359.
96. Evans JC, Bergsjø P. Influence of anemia on the results of radiation therapy in carcinoma of the cervix. Radiology 1965;84:709-716.
97. Bush RS, Jenkin RD, Allt WE et al. Definitive evidence for hypoxic cells influencing cure in cancer therapy. Br J Cancer 1978;37(suppl 3):302-306.
98. Bush RS. The significance of anemia in clinical radiation therapy. Int J Radiat Oncol Biol Phys 1986;12:2047-2050.
99. Cole CJ, Pollack A, Zagars GK et al. Local control of muscle-invasive bladder cancer: Preoperative radiotherapy and cystectomy versus cystectomy alone. Int J Radiat Oncol Biol Phys 1995;32:331-340.
100. Constantinou EC, Daly W, Fung CY et al. Time-dose considerations in the treatment of anal cancer. Int J Radiat Oncol Biol Phys 1997;39:651-657.
101. Dische S. Radiotherapy and anaemia - The clinical experience. Radiother Oncol 1991;20(suppl 1):35-40.
102. Dische S, Saunders MI, Warburton MF. Hemoglobin, radiation, morbidity and survival. Int J Radiat Oncol Biol Phys 1986;12:1335-1337.
103. Dubray B, Mosseri V, Brunin F et al. Anemia is associated with lower local-regional control and survival after radiation therapy for head and neck cancer: A prospective study. Radiology 1996;201:553-558.
104. Dunphy EP, Petersen IA, Cox RS et al. The influence of initial hemoglobin and blood pressure levels on results of radiation therapy for carcinoma of the prostate. Int J Radiat Oncol Biol Phys 1989;16:1173-1178.
105. Fein DA, Lee WR, Hanlon AL et al. Pretreatment hemoglobin level influences local control and survival of T1-T2 squamous cell carcinomas of the glottic larynx. J Clin Oncol 1995;13:2077-2083.
106. Frommhold H, Guttenberger R, Henke M. The impact of blood hemoglobin content on the outcome of radiotherapy: The Freiburg experience. Strahlenther Onkol 1998;174(suppl 4):31-34.
107. Girinski T, Pejovic-Lenfant MH, Bourhis J et al. Prognostic value of hemoglobin concentrations and blood transfusions in advanced carcinoma of the cervix treated by radiation therapy: Results of a retrospective study of 386 patients. Int J Radiat Oncol Biol Phys 1989;16:37-42.
108. Gospodarowicz MK, Hawkins NV, Rawlings GA et al. Radical radiotherapy for muscle invasive transitional cell carcinoma of the bladder: Failure analysis. J Urol 1989;142:1448-1454.
109. Greven KM, Solin LJ, Hanks GE. Prognostic factors in patients with bladder carcinoma treated with definitive irradiation. Cancer 1990;65:908-912.
110. Hannisdal E, Fosså SD, Høst H. Blood tests and prognosis in bladder carcinomas treated with definitive radiotherapy. Radiother Oncol 1993;27:117-122.
111. Hong J-H, Tsai C-S, Chang JT et al. The prognostic significance of pre- and posttreatment SCC levels in patients with squamous cell carcinoma of the cervix treated by radiotherapy. Int J Radiat Oncol Biol Phys 1998;41:823-830.
112. Johansen LV, Overgaard J, Overgaard M et al. Squamous cell carcinoma of the oropharynx: An analysis of 213 consecutive patients scheduled for primary radiotherapy. Laryngoscope 1990;100:985-990.
113. Kagei K, Shirato H, Nishioka T et al. High-dose-rate intracavitary irradiation using linear source arrangement for stage II and III squamous cell carcinoma of the uterine cervix. Radiother Oncol 1998;47:207-213.
114. Kapp DS, Fischer D, Gutierrez E et al. Pretreatment prognostic factors in carcinoma of the uterine cervix: A multivariable analysis of the effect of age, stage, histology and blood counts on survival. Int J Radiat Oncol Biol Phys 1983;9:445-455.
115. Kapp KS, Stuecklschweiger GF, Kapp DS et al. Prognostic factors in patients with carcinoma of the uterine cervix treated with external beam irradiation and IR-192 high-dose-rate brachytherapy. Int J Radiat Oncol Biol Phys 1998;42:531-540.
116. Lee WR, Berkey B, Marcial V et al. Anemia is associated with decreased survival and increased locoregional failure in patients with locally advanced head and neck carcinoma: A secondary analysis of RTOG 85-27. Int J Radiat Oncol Biol Phys 1998;42:1069-1075.
117. Logsdon MD, Eifel PJ. Figo IIIB squamous cell carcinoma of the cervix: An analysis of prognostic factors emphasizing the balance between external beam and intracavitary radiation therapy. Int J Radiat Oncol Biol Phys 1999;43:763-775.
118. Mendenhall WM, Thar TL, Bova FJ et al. Prognostic and treatment factors affecting pelvic control of stage IB and IIA-B carcinoma of the intact uterine cervix treated with radiation therapy alone. Cancer 1984;53:2649-2654.
119. Obralić N, Bilenjki D, Bilbija Ž. Prognostic importance of anemia related parameters in patients with carcinoma of the cervix uteri. Acta Oncol 1990;29:199-201.
120. Pedersen D, Søgaard H, Overgaard J et al. Prognostic value of pretreatment factors in patients with locally advanced carcinoma of the uterine cervix treated by radiotherapy alone. Acta Oncol 1995;34:787-795.
121. Pollack A, Zagars GK, Dinney CP et al. Preoperative radiotherapy for muscle-invasive bladder carcinoma. Cancer 1994;74:2819-2827.
122. Rader JS, Haraf DJ, Halpem HJ et al. Radiation therapy in the treatment of cervical cancer: The University of Chicago/Michael Reese Hospital experience. J Surg Oncol 1990;44:157-165.
123. Skladowski K, Tamawski R, Maciejewski B et al. Clinical radiobiology of glottic T1 squamous cell carcinoma. Int J Radiat Oncol Biol Phys 1999;43:101-106.
124. Takigawa N, Segawa Y, Okahara M et al. Prognostic factors for patients with advanced non-small cell lung cancer: Univariate and multivariate analyses including recursive partitioning and amalgamation. Lung Cancer 1996;15:67-77.
125. Teshima T, Chatani M, Hata K et al. High-dose rate intracavitary therapy for carcinoma of the uterine cervix: I. General figures of survival and complication. Int J Radiat Oncol Biol Phys 1987;13:1035-1041.
126. van Acht MJJ, Hermans J, Boks DES et al. The prognostic value of hemoglobin and a decrease in hemoglobin during radiotherapy in laryngeal carcinoma. Radiother Oncol 1992;23:229-235.
127. Vigario G, Kurohara SS, George FW III. Association of hemoglobin levels before and during radiotherapy with prognosis in uterine cervix cancer. Radiology 1973;106:649-652.
128. Werner-Wasik M, Schmid CH, Bornstein L et al. Prognostic factors for local and distant recurrence in stage I and II cervical carcinoma. Int J Radiat Oncol Biol Phys 1995;32:1309-1317.
129. Grant DG, Hussain A, Hurman D. Pre-treatment anaemia alters outcome in early squamous cell carcinoma of the larynx treated by radical radiotherapy. J Laryngol Otol 1999;113:829-833.
130. Tarnawski R, Skladowski K, Maciejewski B. Prognostic value of hemoglobin concentration in radiotherapy for cancer of supraglottic larynx. Int J Radiat Oncol Biol Phys 1997;38:1007-1011.
131. Guttenberger R, Lutterbach J, Beck C. Anemia is associated with decreased local control of surgically treated squamous cell carcinomas of the glottic larynx. Int J Radiat Oncol Biol Phys 1999;45(suppl 1):203.
132. Becker A, Hänsgen G, Bloching M et al. Oxygenation of squamous cell carcinoma of the head and neck: Comparison of primary tumors, neck node metastases, and normal tissue. Int J Radiat Oncol Biol Phys 1998;42:35-41.
133. Hirst DG. What is the importance of anaemia in radiotherapy? The value of animal studies. Radiother Oncol 1991;20(suppl 1):29-33.
134. Hirst DG. Anemia: A problem or an opportunity in radiotherapy? Int J Radiat Oncol Biol Phys 1986;12:2009-2017.
135. Degner FL, Sutherland RM. Mathematical modelling of oxygen supply and oxygenation in tumor tissues: Prognostic, therapeutic, and experimental implications. Int J Radiat Oncol Biol Phys 1988;15:391-397.
136. Surgenor DM, Wallace EL, Hao SHS et al. Collection and transfusion of blood in the United States, 1982-1988. N Engl J Med 1990;322:1646-1651.
137. Henry DH. Changing patterns of care in the management of anemia. Semin Oncol 1992;19(suppl 8):3-7.
138. Chow E, Danjoux CE, Pataki I et al. Effect of hemoglobin on radiotherapy response in children with medulloblastoma: Should patients with a low hemoglobin be transfused? Med Pediatr Oncol 1999;32:395-397.
139. Lavey RS, Dempsey WH. Erythropoietin increases hemoglobin in cancer patients during radiation therapy. Int J Radiat Oncol Biol Phys 1993;27:1147-1152.
140. Dusenbery KE, McGuire WA, Holt PJ et al. Erythropoietin increases hemoglobin during radiation therapy for cervical cancer. Int J Radiat Oncol Biol Phys 1994;29:1079-1084.
141. Henke M, Guttenberger R, Barke A et al. Erythropoietin for patients undergoing radiotherapy: A pilot study. Radiother Oncol 1999;50:185-190.
142. Sweeney PJ, Nicolae D, Ignacio L et al. Effect of subcutaneous recombinant human erythropoietin in cancer patients receiving radiotherapy: Final report of a randomized, open-labelled, phase II trial. Br J Cancer 1998;77:1996-2002.
143. Shasha D, George MJ, Harrison LB. Once-weekly dosing of epoetin alfa increases hemoglobin and improves quality of life in anemic cancer patients receiving radiation therapy either concomitantly or sequentially with chemotherapy. Blood 2000;96(part IA):434a.
144. Coltman CA. Phase II Study of EPO with Radiotherapy and CDDP for Stage IIB/III/IVA Cervical Carcinoma. Protocol SWOG-9318. Available at: http://www.cancemet.nci.nih.gov. Accessed January 10, 2001.
145. Lavey RS. Clinical trial experience using erythropoietin during radiation therapy. Strahlenther Onkol 1998;174(suppl 4):24-30.
146. Lavey RS, Liu PY, Greer BE et. al. Recombinant human erythropoietin (EPO) as an adjunct to concurrent radiation therapy (RT) and cisplatin for stage IIB-IVA carcinoma of the cervix: A Southwest Oncology Group study. Radiother Oncol 2000;56(suppl 1):S92.
147. Lee JS, Komaki R, Touroutoglou N et al. Erythropoietin (EPO) prevents anemia during concurrent chemoradiation therapy (RT) for locally-advanced inoperable non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 1998;17:463a.
148. Rosen FR, Brockstein BE, Haraf D et al. Multicenter randomized phase II study of 1 hour infusion paclitaxel (T), fluorouracil (5-FU) and hydroxyurea (HU) with concomitant hyperfractionated (BID) radiotherapy (XRT) with or without erythropoietin (EPO) for advanced oral, pharynx and larynx cancer: An interim analysis. Proc Am Soc Clin Oncol 1999;18:393a.
149. Thews O, Koenig R, Kelleher DK et al. Enhanced radiosensitivity in experimental tumours following erythropoietin treatment of chemotherapy-induced anaemia. Br J Cancer 1998;78:752-756.
150. Glaser C, Millesi W, Gössweiner S et al. R-HuErythropoetin supply increases efficacy of neoadjuvant radiochemotherapy in patients with oral squamous cell carcinoma. Proc Am Soc Clin Oncol 1998;17:397a.
151. Glaser C, Millesi W, Wanschitz F et al. R-HuErythropoietin treatment increases efficacy of neoadjuvant radiochemotherapy and improves cancer free survival of patient with oral squamous cell carcinoma: A 17 month follow up. Proc Am Soc Clin Oncol 1999;18:399a.
152. Glaser CM, Millesi W, Komek GV et al. Impact of hemoglobin (Hgb) level and use of recombinant human erythropoietin (r-HuEPO) on response to neoadjuvant chemoradiation therapy, tumor control, and survival in patients with oral or oropharyngeal squamous cell carcinoma (SCCA). Int J Radiat Oncol Biol Phys 1999;45(suppl 1):149.
153. Machtay M. Phase III Randomized Study of Radiotherapy with or Without Epoetin Alfa in Anemic Patients with Squamous Cell Carcinoma of the Head and Neck. Protocol RTOG-9903, RTOGDEV-1008. Available at: http://www.cancemet.nci.nih.gov. Accessed April 4, 2001.